Access up-to-date CAR-T therapy reports for leukemia treatment in China. This section covers key clinical trial findings, long-term follow-up data, safety profiles, and real-world outcomes across ALL, AML (research), and other leukemic conditions. Tailored for international patients and medical professionals, it offers clear, reliable insights into China’s advancements in CAR-T therapy and its growing impact on leukemia care.
A real-world study in China demonstrates that Yorwida CAR-T therapy can improve relapse-free survival in adult B-ALL patients with high-risk genetic features, particularly when used early in CR1-MRD-negative settings.
A real-world analysis of inaticabtagene autoleucel in China demonstrates high response and MRD-negative rates, durable remissions, and favorable safety in adult patients with B-cell acute lymphoblastic leukemia, including high-risk and CNS-involved disease.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.